SCHEMBL23405486

SCHEMBL23405486

COc1ccc(-n2nnc(-c3ccc4c(c3)OCO4)c2N)cc1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.55
TP53 P04637 2/20 0.55
POLB P06746 2/20 0.48
ALDH1A1 P00352 2/20 0.47
XBP1 P17861 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
RIPK2 O43353 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
KIT P10721 1/20 0.41
EDNRB P24530 1/20 0.41
EDNRA P25101 1/20 0.41
FLT3 P36888 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23405497 0.79 POLB (0.62) MAPTTP53POLBALDH1A1MEN1
SCHEMBL23405473 0.78 POLB (0.54) MAPTTP53POLBALDH1A1MEN1
SCHEMBL18385894 0.72 KIT (0.54) MAPTPOLBALDH1A1MEN1KMT2A
SCHEMBL10189660 0.70 ALDH1A1 (0.61) MAPTTP53ALDH1A1XBP1MEN1
SCHEMBL182604 0.69 SRC (0.51) MAPTALDH1A1MEN1KMT2ANPC1
SCHEMBL14619167 0.66 MAPT (0.51) MAPTTP53POLBALDH1A1MEN1
SCHEMBL182389 0.66 PIK3CD (0.58) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL183411 0.66 PIK3CD (0.58) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL3587021 0.65 CD274 (0.52) MAPTTP53POLBALDH1A1XBP1
SCHEMBL548302 0.65 POLB (0.69) MAPTTP53POLBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 US claimed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US claimed
US-12297178-B2 Triazole derivative and use thereof GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2025-05-13 US disclosed
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2024-05-23 US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US disclosed
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF GYEONGGIDO BUSINESS & SCIENCE ACCELERATOR (KR) 2021-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163425-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 MAPT 2951/4885TP53 3433/4885POLB 4310/4885
US-12297178-B2 Triazole derivative and use thereof FABP4, LIPC, GPR119 MAPT 2945/4885TP53 3565/4885POLB 4363/4885
US-20240166611-A1 TRIAZOLE DERIVATIVE AND USE THEREOF FABP4, LIPC, GPR119 MAPT 2945/4885TP53 3565/4885POLB 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.